Skip to main content

Pharmaceutical Technologies (PT)

The Neural Analytics Lucid™ M1 transcranial Doppler Ultrasound System is indicated as an adjunct to the standard clinical practices for measuring and displaying cerebral blood flow velocity within the major conducting arteries and veins of the head and neck. Additionally, the Lucid™ M1 System measures the occurrence of transient emboli signals within the blood stream.

Technology topic

Pharmaceutical Technologies (PT)

The Pharmaceutical Technologies topic covers a wide range of technology areas to advance the discovery, early-stage development and characterization, formulation, delivery, and/or manufacture of novel drugs, moieties, compounds, products, processes, platforms or services that will improve the selection, quality, or price of pharmaceutical and biologic therapies.

The Pharmaceutical Technologies topic is not aimed at supporting or conducting clinical trials, clinical efficacy or safety studies, the development of pre-clinical or clinical-stage drug candidates or medical devices, or work performed primarily for regulatory purposes. Limited studies with human subjects may be acceptable to the extent that they are performed in support of feasibility, proof-of-concept studies of early-stage technologies and must follow NSF policies on research on human subjects. Proposals that request support for clinical studies will be deemed non-compliant with the SBIR/STTR solicitations and may be returned without review.


PT1. Drug Delivery Methods
PT2. Drug Discovery
PT3. Pharmaceutical and Biologic Manufacturing
PT4. Therapeutic Molecules
PT5. Other Pharmaceutical Technologies

Program director

Erik Pierstorff headshot

Erik Pierstorff